Stockreport

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor anta [Read more]